These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3800195)

  • 1. Cirrhotic ascites and hyperemia in the splanchnic vasculature.
    Bredfeldt JE
    Ann Intern Med; 1987 Feb; 106(2):328-9. PubMed ID: 3800195
    [No Abstract]   [Full Text] [Related]  

  • 2. Haemodynamic changes in portal hypertension: new insights in the pathogenesis and clinical implications.
    Michielsen PP; Pelckmans PA
    Acta Gastroenterol Belg; 1994; 57(2):194-205. PubMed ID: 8053307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiopathology of ascites in portal hypertension.
    Michielsen PP
    Acta Gastroenterol Belg; 1996; 59(3):191-7. PubMed ID: 9015930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splanchnic endotoxin levels in cirrhotic rats induced by carbon tetrachloride.
    Chu CJ; Lee FY; Wang SS; Chang FY; Lin HC; Lu RH; Chan CC; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):196-204. PubMed ID: 10746415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of glucagon in splanchnic hyperemia of chronic portal hypertension.
    Benoit JN; Zimmerman B; Premen AJ; Go VL; Granger DN
    Am J Physiol; 1986 Nov; 251(5 Pt 1):G674-7. PubMed ID: 3777172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.
    Angermayr B; Fernandez M; Mejias M; Gracia-Sancho J; Garcia-Pagan JC; Bosch J
    Gut; 2007 Apr; 56(4):560-4. PubMed ID: 16854998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
    Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
    Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperdynamic circulation in portal hypertension: a comparative model of arterio-venous fistula.
    Wattanasirichaigoon S; Gordon FD; Resnick RH
    Med Hypotheses; 2000 Jul; 55(1):77-87. PubMed ID: 11021333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splanchnic circulatory and tissue fluid dynamics in portal hypertension.
    Witte CL; Witte MH
    Fed Proc; 1983 Apr; 42(6):1685-9. PubMed ID: 6832387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Physiopathology of refractory ascites and the hepatorenal syndrome].
    Arroyo V
    Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension.
    Sitzmann JV; Bulkley GB; Mitchell MC; Campbell K
    Ann Surg; 1989 Mar; 209(3):322-7. PubMed ID: 2493776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restriction of drinking water abrogates splanchnic vasodilation and portal hypertension in portal vein-ligated rats.
    Heinemann A; Schuligoi R; Lippe IT; Stauber RE
    Pharmacology; 2009; 83(1):26-32. PubMed ID: 18987488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of glucagon improves splanchnic hyporesponse to terlipressin in cirrhotic rats with blood retention in the gastric lumen.
    Yang YY; Lin HC; Huang YT; Hou MC; Lee FY; Chang FY; Lee SD
    J Hepatol; 2005 May; 42(5):652-8. PubMed ID: 15826713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension.
    Sitzmann JV; Campbell K; Wu Y; St Clair C
    Surgery; 1994 Mar; 115(3):290-4. PubMed ID: 8128353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
    Yang YY; Liu RS; Lee PC; Yeh YC; Huang YT; Lee WP; Lee KC; Hsieh YC; Lee FY; Tan TW; Lin HC
    Liver Int; 2014 Apr; 34(4):521-34. PubMed ID: 23998651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats.
    Coch L; Mejias M; Berzigotti A; Garcia-Pras E; Gallego J; Bosch J; Mendez R; Fernandez M
    Hepatology; 2014 Aug; 60(2):633-47. PubMed ID: 24390792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NPY for vasoregulation in the splanchnic circulation during portal hypertension.
    Wiest R; Jurzik L; Herold T; Straub RH; Schölmerich J
    Peptides; 2007 Feb; 28(2):396-404. PubMed ID: 17194504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascites: diagnosis and management.
    Hou W; Sanyal AJ
    Med Clin North Am; 2009 Jul; 93(4):801-17, vii. PubMed ID: 19577115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal sodium retention and ascites formation in dogs with experimental cirrhosis but without portal hypertension or increased splanchnic vascular capacity.
    Levy M; Wexler MJ
    J Lab Clin Med; 1978 Mar; 91(3):520-36. PubMed ID: 627753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.
    Martin PY; Ginès P; Schrier RW
    N Engl J Med; 1998 Aug; 339(8):533-41. PubMed ID: 9709047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.